查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1701807

2025 年至 2033 年疫苗市場報告（按技術、患者類型、適應症、給藥途徑、產品類型、治療類型、最終用戶、配銷通路和地區分類）

Vaccine Market Report by Technology, Patient Type, Indication, Route of Administration, Product Type, Treatment Type, End User, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

2024年全球疫苗市場規模達598億美元。展望未來， IMARC Group預計到2033年市場規模將達到1,365億美元，2025-2033年期間的成長率（CAGR）為9.12%。推動個人接種疫苗的嚴格法規的實施、生物技術和疫苗開發技術的若干進步以及民眾對疫苗接種重要性的日益增強的健康意識是推動市場發展的一些主要因素。

疫苗是公共衛生的重要工具，旨在預防和控制傳染病的傳播。它們本質上是刺激免疫系統識別和對抗特定病原體（如細菌或病毒）的生物製劑。它們含有目標病原體的弱化或去活化形式或其片段，稱為抗原。接種疫苗時，疫苗會模擬感染，促使免疫系統產生抗體並形成免疫記憶。此外，當個體接觸到實際病原體時，它能確保免疫系統迅速發動防禦，有效預防疾病或減輕其嚴重程度。

市場的主要驅動力是人們日益成長的健康問題。此外，最近爆發的冠狀病毒病（COVID-19）疫情提高了人們對產品在維護公共健康方面的重要性的認知，從而促進了市場的成長。此外，mRNA 產品等新型疫苗技術的開發正在透過提供更快、更精確的疫苗開發能力來改變整個產業，有效應對新出現的威脅，從而成為另一個主要的成長誘因。除此之外，製藥公司正在擴大其疫苗組合，包括針對傳統疾病以外的各種疾病的疫苗，從而開闢了新的市場和收入來源，從而加速了銷售需求。除此之外，政府採取的多項舉措，包括疫苗接種運動、公眾意識宣傳活動以及為遏制疾病傳播而提供的疫苗研究資金，正在推動市場成長。此外，公共和私營部門正在進行的疫苗研發投資（R&D）確保了新產品的強勁供應，從而創造了積極的市場前景。

疫苗市場趨勢/促進因素：

實施嚴格的法規，促進接種疫苗

該市場受到旨在促進個人接種疫苗的嚴格法規的實施所推動。此外，對疫苗安全性和有效性的日益重視也促進了市場的成長。此外，製造商堅持嚴格的測試和品質控制措施，以確保產品符合最高的安全標準，從而增加對研發（R&D）的投資，以創造出有效預防疾病且副作用最小的產品，從而成為另一個主要的成長誘導因素。除此之外，該公司還提供有關其產品的清晰全面的資訊，包括潛在的副作用和禁忌症，使個人能夠對疫苗接種做出明智的決定，從而加快產品採用率。除此之外，各國政府和醫療機構正在實施各種激勵計劃，包括補貼、公眾意識宣傳活動，在某些情況下還鼓勵接種疫苗，從而推動市場成長。

生物技術和疫苗開發技術的多項進展

生物技術和疫苗開發技術的幾項顯著進步推動了市場的發展。它正在改變疫苗的設計和製造方式，有助於開發高效、有針對性的疫苗。此外，基因組學和分子生物學在疫苗開發中的應用使科學家能夠以前所未有的速度和精度解碼病原體的遺傳訊息，使他們能夠更有效地識別潛在的候選疫苗，從而開發出針對 COVID-19 等新興疾病的產品，從而促進了市場的成長。此外，重組脫氧核糖核酸（DNA）技術的幾項進步使得重組疫苗的產生成為可能，這種疫苗可以在不引起疾病本身的情況下刺激增強的免疫反應，從而有效預防包括乙肝和人類乳突病毒在內的傳染病，從而成為另一個主要的經濟成長誘因。此外，合成生物學技術的應用也促進了多項創新，使科學家能夠精確設計和合成疫苗成分，以開發針對挑戰性病原體的新型疫苗，從而創造積極的市場前景。

人們越來越意識到疫苗接種的重要性

市場的發展受到人們日益增強的健康意識（對疫苗接種的重要性的認知）的推動。此外，最近爆發的冠狀病毒病 (COVID-19) 疫情提高了公眾對疫苗接種價值的認知，從而促進了市場的成長。同時，製造商正在開發和分發疫苗對抗病毒，同時專注於疫苗的有效性、安全性和可及性，從而推動市場成長。此外，透過醫療保健提供者、政府機構和媒體等各種管道傳播準確的資訊以保障公眾健康，這是另一個重要的成長誘因。除此之外，社群媒體和數位平台的興起在提供疫苗接種資訊方面發揮了重要作用，使個人能夠獲得可靠的資源並參與知情討論。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢
    • 監管格局
      • 美國
      • 加拿大
      • 歐洲聯盟
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲
      • 俄羅斯
      • 巴西
      • 墨西哥
      • 土耳其
      • 海灣合作理事會國家
      • 以色列
    • 新疫苗產品線
      • HIV產品線
      • 寨卡病毒產品線
      • 伊波拉病毒產品線
      • COVID-19 產品線

第5章：全球疫苗市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依技術

  • 結合疫苗
  • 去活化疫苗和次單位疫苗
  • 減毒活疫苗
  • 重組疫苗
  • 類毒素疫苗
  • 其他

第7章：市場區隔：依患者類型

  • 兒科
  • 成人

第8章：市場區隔：依指標

  • 細菌性疾病
    • 主要類型
      • 腦膜炎球菌疾病
      • 肺炎球菌疾病
      • 白喉/破傷風/百日咳（DPT）
      • 結核
      • 流感嗜血桿菌（Hib）
      • 傷寒
      • 其他
  • 病毒性疾病
    • 主要類型
      • 肝炎
      • 流感
      • 人類乳突病毒（HPV）
      • 麻疹/腮腺炎/德國麻疹 (MMR)
      • 輪狀病毒
      • 帶狀皰疹
      • 水痘
      • 日本腦炎
      • 風疹
      • 小兒麻痺
      • 狂犬病
      • 登革熱
      • 其他

第9章：市場細分：依行政途徑

  • 肌肉注射和皮下注射
  • 口服
  • 其他

第10章：市場區隔：依產品類型

  • 多價疫苗
  • 單價疫苗

第 11 章：市場區隔：依治療類型

  • 預防疫苗
  • 治療性疫苗

第 12 章：市場區隔：依最終用戶

  • 醫院
  • 診所
  • 疫苗接種中心
  • 學術和研究機構
  • 其他

第13章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 機構銷售
  • 其他

第 14 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 土耳其
    • 海灣合作理事會國家
    • 以色列
    • 其他

第 15 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 16 章：價值鏈分析

  • 探索階段
  • 臨床前和臨床開發
  • 監管部門批准
  • 製造業
  • 行銷與分銷

第 17 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 18 章：價格分析

第19章：主要促進因素與挑戰

第 20 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bharat Biotech International
    • Bavarian Nordic A/S
    • CSL Limited
    • Daiichi Sankyo Company Limited
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline Plc
    • Inovio Pharmaceuticals Inc.
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
    • Novavax Inc.
    • Panacea Biotec Ltd.
    • Pfizer Inc.
    • Sanofi Pasteur SA (Sanofi SA)
    • Serum Institute of India Pvt. Ltd.
    • Takeda Pharmaceutical Company Limited
Product Code: SR112025A2374

The global vaccine market size reached USD 59.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 136.5 Billion by 2033, exhibiting a growth rate (CAGR) of 9.12% during 2025-2033. The implementation of stringent regulations promoting the adoption of vaccination among individuals, several advances in biotechnology and vaccine development techniques, and the growing health awareness among the population about the importance of vaccination are some of the major factors propelling the market.

Vaccines are essential tools in public health, designed to prevent and control the spread of infectious diseases. They are essentially biological preparations that stimulate the immune system to recognize and fight specific pathogens, such as bacteria or viruses. They contain weakened or inactivated forms of the target pathogen or pieces of it, known as antigens. When administered, vaccination mimic an infection, prompting the immune system to produce antibodies and develop immune memory. Additionally, it ensures immune system to swiftly mount a defense, effectively preventing illness or reducing its severity, when the individual is exposed to the actual pathogen.

The market is primarily driven by the growing health concerns among individuals. In addition, the recent onset of the coronavirus disease (COVID-19) pandemic raised awareness among individuals regarding the importance of the product in safeguarding public health, thus augmenting the market growth. Moreover, the development of novel vaccine technologies, such as mRNA products are transforming the industry by offering faster and precise vaccine development capabilities, addressing emerging threats effectively, thus representing another major growth-inducing factor. Besides this, pharmaceutical companies are expanding their vaccine portfolios to include vaccinations for various diseases beyond the traditional ones which opened new markets and revenue streams, thus accelerating the sales demand. Along with this, several government initiatives including vaccination drives, public awareness campaigns, and funding for vaccine research to curb the spread of diseases are propelling the market growth. Furthermore, the ongoing vaccine research and development investment (R&D) in public and private sectors ensures a robust pipeline of new products, thus creating a positive market outlook.

Vaccine Market Trends/Drivers:

The implementation of stringent regulations promoting the adoption of vaccination

The market is driven by the enforcement of stringent regulations aimed at promoting vaccination among individuals. In addition, the growing emphasis on vaccine safety and efficacy is augmenting the market growth. Moreover, manufacturers adhere to rigorous testing and quality control measures to ensure that products meet the highest standards of safety, resulting in rising investment in research and development (R&D) to create products that prevent diseases effectively and have minimal adverse effects, thus representing another major growth-inducing factor. Besides this, companies are providing clear and comprehensive information about their products, including potential side effects and contraindications which empowers individuals to make informed decisions about vaccination, thus accelerating the product adoption rate. Along with this, various governments and healthcare authorities are implementing various incentive programs including subsidies, public awareness campaigns, and mandates in some cases encouraging the adoption of vaccination, thus propelling the market growth.

Several advances in biotechnology and vaccine development techniques

The market is driven by several remarkable advances in biotechnology and vaccine development techniques. It is transforming the way vaccinations are designed and manufactured which is contributing to the development of highly effective and targeted vaccinations. In addition, the utilization of genomics and molecular biology in vaccine development led scientists to decode the genetic information of pathogens with unprecedented speed and precision, enabling them to identify potential vaccine candidates more efficiently, resulting in the development of products against emerging diseases such as COVID-19, thus augmenting the market growth. Moreover, several advancements in recombinant deoxyribonucleic acid (DNA) technology allowed for the creation of recombinant vaccinations, stimulating enhanced immune response without causing the disease itself which is effective in preventing infectious diseases, including hepatitis B and human papillomavirus, thus representing another major growth-induing factor. Furthermore, the application of synthetic biology techniques is also contributing to several innovations, allowing scientists to design and synthesize vaccine components with precision, for the development of novel vaccinations against challenging pathogens, thus creating a positive market outlook.

The growing awareness about the importance of vaccination

The market is driven by the growing health awareness among individuals regarding the importance of vaccination. In addition, the recent onset of the coronavirus disease (COVID-19) pandemic raised public awareness about the value of vaccination, thus augmenting the market growth. Along with this, manufacturers are developing and distributing vaccinations to combat the virus while focusing on vaccine efficacy, safety, and accessibility, thus propelling the market growth. Moreover, the dissemination of accurate information through various channels, including healthcare providers, government agencies, and the media to safeguard public health, which represents another major growth-inducing factor. Besides this, the rise of social media and digital platforms played a significant part in providing information about vaccinations, enabling individuals to access reliable resources and engage in informed discussions.

Vaccine Industry Segmentation:

Breakup by Technology:

  • Conjugate Vaccines
  • Inactivated and Subunit Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines
  • Others

Conjugate products are gaining popularity due to their effectiveness in preventing bacterial infections. They are designed to elicit a strong immune response and are particularly used for diseases such as haemophilus influenzae type B (Hib) and streptococcus pneumoniae.

Moreover, inactivated and subunit products are widely used for viral diseases, such as influenza, hepatitis B, and human papillomavirus (HPV) which contain components of the pathogen, ensuring safety while still providing immunity, thus representing another major growth-inducing factor. Besides this, Live attenuated vaccines are created from weakened forms of pathogens and are effective against diseases such as measles, mumps, and rubella which are essential in disease eradication programs, thus accelerating the sales demand.

Along with this, recombinant products use genetic engineering to create vaccinations against diseases such as hepatitis B and human papillomavirus and offer potential for customization and efficacy, thus propelling the market growth. Also, toxoid vaccinations are employed for bacterial diseases including diphtheria and tetanus due to their long-lasting immunity benefits, thus augmenting the market growth.

Breakup by Patient Type:

  • Pediatric
  • Adult

Pediatric patients hold the largest share of the market

The pediatrics segment is driven by the growing emphasis on immunization, thus influencing the market growth. Moreover, governments and healthcare organizations are preventing childhood diseases, leading to increasing vaccination programs and investments in pediatric vaccine research, thus contributing to market growth.

Moreover, several advancements in vaccine technology made it possible to develop safer and more effective vaccinations for children, resulting in a steady stream of new vaccinations tailored specifically for pediatric populations, representing another major growth-inducing factor.

Additionally, the COVID-19 pandemic underscored the importance of vaccinations for children. Efforts to vaccinate children against the virus further increase the role of pediatrics in the vaccine industry, thus propelling the market growth.

Breakup by Indication:

  • Bacterial Diseases
    • Meningococcal Disease
    • Pneumococcal Disease
    • Diphtheria/Tetanus/Pertussis (DPT)
    • Tuberculosis
    • Haemophilus Influenzae (Hib)
    • Typhoid
    • Others
  • Viral Diseases
    • Hepatitis
    • Influenza
    • Human Papillomavirus (HPV)
    • Measles/Mumps/Rubella (MMR)
    • Rotavirus
    • Herpes Zoster
    • Varicella
    • Japanese Encephalitis
    • Rubella
    • Polio
    • Rabies
    • Dengue
    • Others

Bacterial diseases presently account for the largest market share

The market is driven by the growing incidences of bacterial diseases, caused by various bacteria such as Streptococcus pneumoniae and Haemophilus influenzae. In addition, the increasing development of effective vaccinations to prevent these infections is augmenting the market growth.

Furthermore, several advancements in vaccine technology are improving bacterial disease vaccinations. Along with this, several innovations in research and development (R&D) yielded vaccinations that are effective and safe for widespread use which are designed to stimulate the body's immune response, thereby conferring immunity against bacterial pathogens, thus propelling the market growth.

Breakup by Route of Administration:

  • Intramuscular and Subcutaneous Administration
  • Oral Administration
  • Others

Intramuscular and subcutaneous administration represents the leading segment

Intramuscular administration involves injecting vaccinations directly into the muscle tissue which offers several advantages. In addition, muscles have an abundant blood supply, allowing for efficient uptake and distribution of the vaccine components leading to improved immune response, thus influencing the market growth. Along with this, IM injections often require larger needles, which can facilitate the administration of vaccinations with thicker formulations or those containing adjuvants, thus augmenting the market growth.

Moreover, subcutaneous administration involves injecting vaccinations into the fatty tissue just beneath the skin which is preferred for products that are well-suited for slower, sustained release into the bloodstream, thus representing another major growth-inducing factor. It is less invasive and typically uses smaller needles, making it a preferred choice among individuals who may be apprehensive about needles.

Breakup by Product Type:

  • Multivalent Vaccine
  • Monovalent Vaccine

Multivalent vaccine represent the most used product type

Multivalent offers a streamlined approach to immunization by combining antigens from different pathogens into a single vaccine, which reduces the number of injections required, minimizing discomfort for patients and simplifying vaccination schedules, thus augmenting the market growth.

Furthermore, multivalent vaccinations are efficient in preventing several diseases. For instance, combination vaccinations such as the measles, mumps, and rubella (MMR) vaccinations are eliminating these diseases in many regions, resulting in extensive research and development (R&D) efforts in the field, thus propelling the market growth.

Along with this, multivalent vaccinations offer substantial advantages, as the production, distribution, and administration of a single vaccine covering multiple diseases are more efficient and economical compared to individual vaccinations for each pathogen, thus accelerating the product adoption rate among healthcare systems and patients.

Breakup by Treatment Type:

  • Preventive Vaccine
  • Therapeutic Vaccine

Preventive vaccine currently dominates the market

Preventive vaccinations are designed to proactively protect individuals from contracting specific diseases. They achieve this by stimulating the immune system to produce antibodies that recognize and neutralize pathogens, such as viruses or bacteria, should the individual be exposed to them in the future has proven to be highly effective in reducing the incidence and severity of various illnesses.

Moreover, it has immense success in eradicating or controlling life-threatening diseases. Some historical examples include the near-eradication of smallpox through vaccination and the significant reduction in polio cases which are essential in fighting against infectious diseases. Furthermore, the rapid development and distribution of products to combat the virus and save countless lives are propelling the market growth.

Breakup by End User:

  • Hospitals
  • Clinics
  • Vaccination Centers
  • Academic and Research Institutes
  • Others

Hospitals hold the largest share of the market

The hospital industry is driven by its strategic position as a primary healthcare provider. In addition, hospitals serve as the frontline of defense against infectious diseases, making them the ideal setting for vaccine dissemination which possesses the necessary infrastructure, medical personnel, and resources to efficiently handle the storage, distribution, and administration of products, thus propelling the market growth.

Furthermore, hospitals are essential in vaccination advocacy and education. They are trusted sources of healthcare information, and their healthcare professionals serve as product advocates through patient consultations, seminars, and informational campaigns. Along with this, hospitals are promoting the importance of vaccination, contributing to higher vaccination rates and public awareness.

Along with this, hospitals also engage in product research and development (R&D), partnering with pharmaceutical companies and research institutions to conduct clinical trials and assess vaccination efficacy, thus contributing to market growth.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Sales
  • Others

Hospital pharmacies presently account for the largest market share

Hospital pharmacies are located at the heart of healthcare facilities which ensures that vaccinations are easily accessible to healthcare professionals and patients. Hospitals are often the first point of contact for individuals seeking vaccination, whether it's for routine immunizations or during public health emergencies.

Moreover, hospital pharmacies have the infrastructure and trained staff necessary to handle and administer products safely while adhering to strict quality control and storage protocols, ensuring the integrity and efficacy of vaccinations throughout the distribution process, thus representing another major growth-inducing factor. This reliability and commitment to maintaining the cold chain are essential for preserving the potency of products.

Along with this, hospital pharmacies benefit from established relationships with healthcare providers and government agencies responsible for vaccination programs which allows for seamless coordination in vaccination procurement, distribution, and administration, thus propelling the market growth. Also, hospitals serve as vaccination hubs during mass immunization campaigns, further solidifying their role in the market.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
    • Turkey
    • GCC Countries
    • Israel
    • Others

Asia Pacific exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share.

The Asia Pacific market is driven by the growing pharmaceutical and biotechnology sector. In addition, several countries such as India and China are investing heavily in the development of their healthcare infrastructure, research capabilities, and manufacturing capacities, allowing them to produce vaccination at scale, often at a lower cost than their Western counterparts. thus, contributing to the market growth.

Additionally, the rising pool of skilled scientists, researchers, and healthcare professionals is augmenting the market growth. These experts are driving innovation and ensuring the quality and safety of vaccinations produced in the region. Furthermore, the region offers ample opportunities for clinical trials and testing, allowing for the accelerated development of new products, thus accelerating the sales demand.

Apart from this, the strategic partnerships and collaborations among pharmaceutical companies in the region are facilitating technology transfer, knowledge sharing, and access to critical resources, strengthening the region's position in the market.

Competitive Landscape:

At present, key players in the market are taking strategic initiatives to strengthen their positions in the competitive landscape of the market research and consulting services industry. These actions are vital for maintaining their relevance and authority in the field. They are embracing advanced technologies including artificial intelligence, machine learning, and data analytics which help in delivering more accurate and actionable insights, that is highly valued by clients. Moreover, companies are establishing thought leadership through content marketing and thought-provoking research reports which help in showcasing expertise and attract clients who seek industry insights. Besides this, they are focusing on client satisfaction and building long-term relationships by providing personalized services and tailored solutions based on client requirements that enhance trust and loyalty.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bharat Biotech International
  • Bavarian Nordic A/S
  • CSL Limited
  • Daiichi Sankyo Company Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
  • Novavax Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi Pasteur SA (Sanofi SA)
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited.

Recent Developments:

  • In September 2020, the Serum Institute of India Pvt. Ltd., partnered with Gavi and the Bill & Melinda Gates Foundation to accelerate the production and distribution of an additional 100 million doses of COVID-19 vaccines that are safe and effective.
  • In April 2023, Pfizer Inc., announced data from phase 3 trials of its RSV shots. The trial conducted in adult patients demonstrated that the shot was 67% more effective in preventing infections with two related symptoms and 86% effective in case of severe disease. The successful approval of this vaccine will make it the first product in the RSV market.
  • In June 2022, GlaxoSmithKline Plc officially submitted a Biologics License Application (BLA) to the United States Food and Drug Administration (USFDA) for their experimental vaccine known as PRIORIX, which originally registered in Germany, has received licenses from more than 100 countries.

Key Questions Answered in This Report

  • 1.What was the size of the global vaccine market in 2024?
  • 2.What is the expected growth rate of the global vaccine market during 2025-2033?
  • 3.What are the key factors driving the global vaccine market?
  • 4.What has been the impact of COVID-19 on the global vaccine market?
  • 5.What is the breakup of the global vaccine market based on the patient type?
  • 6.What is the breakup of the global vaccine market based on the indication?
  • 7.What is the breakup of the global vaccine market based on the route of administration?
  • 8.What is the breakup of the global vaccine market based on the product type?
  • 9.What is the breakup of the global vaccine market based on the treatment type?
  • 10.What is the breakup of the global vaccine market based on the end user?
  • 11.What is the breakup of the global vaccine market based on the distribution channel?
  • 12.What are the key regions in the global vaccine market?
  • 13.Who are the key players/companies in the global vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends
    • 4.2.1 Regulatory Landscape
      • 4.2.1.1 United States
      • 4.2.1.2 Canada
      • 4.2.1.3 European Union
      • 4.2.1.4 China
      • 4.2.1.5 India
      • 4.2.1.6 Japan
      • 4.2.1.7 South Korea
      • 4.2.1.8 Australia
      • 4.2.1.9 Russia
      • 4.2.1.10 Brazil
      • 4.2.1.11 Mexico
      • 4.2.1.12 Turkey
      • 4.2.1.13 GCC Countries
      • 4.2.1.14 Israel
    • 4.2.2 Product Pipeline for New Vaccines
      • 4.2.2.1 Product Pipeline for HIV
      • 4.2.2.2 Product Pipeline for Zika Virus
      • 4.2.2.3 Product Pipeline for Ebola Virus
      • 4.2.2.4 Product Pipeline for COVID-19

5 Global Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Conjugate Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Inactivated and Subunit Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Live Attenuated Vaccines
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Recombinant Vaccines
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Toxoid Vaccines
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Patient Type

  • 7.1 Paediatric
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Adult
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Bacterial Diseases
    • 8.1.1 Market Trends
    • 8.1.2 Major Types
      • 8.1.2.1 Meningococcal Disease
        • 8.1.2.1.1 Market Trends
        • 8.1.2.1.2 Market Forecast
      • 8.1.2.2 Pneumococcal Disease
        • 8.1.2.2.1 Market Trends
        • 8.1.2.2.2 Market Forecast
      • 8.1.2.3 Diphtheria/Tetanus/Pertussis (DPT)
        • 8.1.2.3.1 Market Trends
        • 8.1.2.3.2 Market Forecast
      • 8.1.2.4 Tuberculosis
        • 8.1.2.4.1 Market Trends
        • 8.1.2.4.2 Market Forecast
      • 8.1.2.5 Haemophilus Influenzae (Hib)
        • 8.1.2.5.1 Market Trends
        • 8.1.2.5.2 Market Forecast
      • 8.1.2.6 Typhoid
        • 8.1.2.6.1 Market Trends
        • 8.1.2.6.2 Market Forecast
      • 8.1.2.7 Others
        • 8.1.2.7.1 Market Trends
        • 8.1.2.7.2 Market Forecast
    • 8.1.3 Market Forecast
  • 8.2 Viral Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Major Types
      • 8.2.2.1 Hepatitis
        • 8.2.2.1.1 Market Trends
        • 8.2.2.1.2 Market Forecast
      • 8.2.2.2 Influenza
        • 8.2.2.2.1 Market Trends
        • 8.2.2.2.2 Market Forecast
      • 8.2.2.3 Human Papillomavirus (HPV)
        • 8.2.2.3.1 Market Trends
        • 8.2.2.3.2 Market Forecast
      • 8.2.2.4 Measles/Mumps/Rubella (MMR)
        • 8.2.2.4.1 Market Trends
        • 8.2.2.4.2 Market Forecast
      • 8.2.2.5 Rotavirus
        • 8.2.2.5.1 Market Trends
        • 8.2.2.5.2 Market Forecast
      • 8.2.2.6 Herpes Zoster
        • 8.2.2.6.1 Market Trends
        • 8.2.2.6.2 Market Forecast
      • 8.2.2.7 Varicella
        • 8.2.2.7.1 Market Trends
        • 8.2.2.7.2 Market Forecast
      • 8.2.2.8 Japanese Encephalitis
        • 8.2.2.8.1 Market Trends
        • 8.2.2.8.2 Market Forecast
      • 8.2.2.9 Rubella
        • 8.2.2.9.1 Market Trends
        • 8.2.2.9.2 Market Forecast
      • 8.2.2.10 Polio
        • 8.2.2.10.1 Market Trends
        • 8.2.2.10.2 Market Forecast
      • 8.2.2.11 Rabies
        • 8.2.2.11.1 Market Trends
        • 8.2.2.11.2 Market Forecast
      • 8.2.2.12 Dengue
        • 8.2.2.12.1 Market Trends
        • 8.2.2.12.2 Market Forecast
      • 8.2.2.13 Others
        • 8.2.2.13.1 Market Trends
        • 8.2.2.13.2 Market Forecast
    • 8.2.3 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Intramuscular and Subcutaneous Administration
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Oral Administration
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Product Type

  • 10.1 Multivalent Vaccine
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Monovalent Vaccine
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Treatment Type

  • 11.1 Preventive Vaccine
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Therapeutic Vaccine
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast

12 Market Breakup by End User

  • 12.1 Hospitals
    • 12.1.1 Market Trends
    • 12.1.2 Market Forecast
  • 12.2 Clinics
    • 12.2.1 Market Trends
    • 12.2.2 Market Forecast
  • 12.3 Vaccination Centres
    • 12.3.1 Market Trends
    • 12.3.2 Market Forecast
  • 12.4 Academic and Research Institutes
    • 12.4.1 Market Trends
    • 12.4.2 Market Forecast
  • 12.5 Others
    • 12.5.1 Market Trends
    • 12.5.2 Market Forecast

13 Market Breakup by Distribution Channel

  • 13.1 Hospital Pharmacies
    • 13.1.1 Market Trends
    • 13.1.2 Market Forecast
  • 13.2 Retail Pharmacies
    • 13.2.1 Market Trends
    • 13.2.2 Market Forecast
  • 13.3 Institutional Sales
    • 13.3.1 Market Trends
    • 13.3.2 Market Forecast
  • 13.4 Others
    • 13.4.1 Market Trends
    • 13.4.2 Market Forecast

14 Market Breakup by Region

  • 14.1 North America
    • 14.1.1 United States
      • 14.1.1.1 Market Trends
      • 14.1.1.2 Market Forecast
    • 14.1.2 Canada
      • 14.1.2.1 Market Trends
      • 14.1.2.2 Market Forecast
  • 14.2 Asia Pacific
    • 14.2.1 China
      • 14.2.1.1 Market Trends
      • 14.2.1.2 Market Forecast
    • 14.2.2 Japan
      • 14.2.2.1 Market Trends
      • 14.2.2.2 Market Forecast
    • 14.2.3 India
      • 14.2.3.1 Market Trends
      • 14.2.3.2 Market Forecast
    • 14.2.4 South Korea
      • 14.2.4.1 Market Trends
      • 14.2.4.2 Market Forecast
    • 14.2.5 Australia
      • 14.2.5.1 Market Trends
      • 14.2.5.2 Market Forecast
    • 14.2.6 Others
      • 14.2.6.1 Market Trends
      • 14.2.6.2 Market Forecast
  • 14.3 Europe
    • 14.3.1 Germany
      • 14.3.1.1 Market Trends
      • 14.3.1.2 Market Forecast
    • 14.3.2 France
      • 14.3.2.1 Market Trends
      • 14.3.2.2 Market Forecast
    • 14.3.3 United Kingdom
      • 14.3.3.1 Market Trends
      • 14.3.3.2 Market Forecast
    • 14.3.4 Italy
      • 14.3.4.1 Market Trends
      • 14.3.4.2 Market Forecast
    • 14.3.5 Spain
      • 14.3.5.1 Market Trends
      • 14.3.5.2 Market Forecast
    • 14.3.6 Russia
      • 14.3.6.1 Market Trends
      • 14.3.6.2 Market Forecast
    • 14.3.7 Others
      • 14.3.7.1 Market Trends
      • 14.3.7.2 Market Forecast
  • 14.4 Latin America
    • 14.4.1 Brazil
      • 14.4.1.1 Market Trends
      • 14.4.1.2 Market Forecast
    • 14.4.2 Mexico
      • 14.4.2.1 Market Trends
      • 14.4.2.2 Market Forecast
    • 14.4.3 Others
      • 14.4.3.1 Market Trends
      • 14.4.3.2 Market Forecast
  • 14.5 Middle East and Africa
    • 14.5.1 Turkey
      • 14.5.1.1 Market Trends
      • 14.5.1.2 Market Forecast
    • 14.5.2 GCC Countries
      • 14.5.2.1 Market Trends
      • 14.5.2.2 Market Forecast
    • 14.5.3 Israel
      • 14.5.3.1 Market Trends
      • 14.5.3.2 Market Forecast
    • 14.5.4 Others
      • 14.5.4.1 Market Trends
      • 14.5.4.2 Market Forecast

15 SWOT Analysis

  • 15.1 Overview
  • 15.2 Strengths
  • 15.3 Weaknesses
  • 15.4 Opportunities
  • 15.5 Threats

16 Value Chain Analysis

  • 16.1 Exploratory Stage
  • 16.2 Preclinical and Clinical Development
  • 16.3 Regulatory Approval
  • 16.4 Manufacturing
  • 16.5 Marketing and Distribution

17 Porters Five Forces Analysis

  • 17.1 Overview
  • 17.2 Bargaining Power of Buyers
  • 17.3 Bargaining Power of Suppliers
  • 17.4 Degree of Competition
  • 17.5 Threat of New Entrants
  • 17.6 Threat of Substitutes

18 Price Analysis

19 Major Drivers and Challenges

20 Competitive Landscape

  • 20.1 Market Structure
  • 20.2 Key Players
  • 20.3 Profiles of Key Players
    • 20.3.1 Abbott Laboratories
      • 20.3.1.1 Company Overview
      • 20.3.1.2 Product Portfolio
      • 20.3.1.3 Financials
      • 20.3.1.4 SWOT Analysis
    • 20.3.2 Astellas Pharma Inc.
      • 20.3.2.1 Company Overview
      • 20.3.2.2 Product Portfolio
      • 20.3.2.3 Financials
      • 20.3.2.4 SWOT Analysis
    • 20.3.3 AstraZeneca Plc
      • 20.3.3.1 Company Overview
      • 20.3.3.2 Product Portfolio
      • 20.3.3.3 Financials
      • 20.3.3.4 SWOT Analysis
    • 20.3.4 Bharat Biotech International
      • 20.3.4.1 Company Overview
      • 20.3.4.2 Product Portfolio
    • 20.3.5 Bavarian Nordic A/S
      • 20.3.5.1 Company Overview
      • 20.3.5.2 Product Portfolio
      • 20.3.5.3 Financials
    • 20.3.6 CSL Limited
      • 20.3.6.1 Company Overview
      • 20.3.6.2 Product Portfolio
      • 20.3.6.3 Financials
      • 20.3.6.4 SWOT Analysis
    • 20.3.7 Daiichi Sankyo Company Limited
      • 20.3.7.1 Company Overview
      • 20.3.7.2 Product Portfolio
    • 20.3.8 Emergent BioSolutions Inc.
      • 20.3.8.1 Company Overview
      • 20.3.8.2 Product Portfolio
      • 20.3.8.3 Financials
      • 20.3.8.4 SWOT Analysis
    • 20.3.9 GlaxoSmithKline Plc
      • 20.3.9.1 Company Overview
      • 20.3.9.2 Product Portfolio
      • 20.3.9.3 Financials
      • 20.3.9.4 SWOT Analysis
    • 20.3.10 Inovio Pharmaceuticals Inc.
      • 20.3.10.1 Company Overview
      • 20.3.10.2 Product Portfolio
      • 20.3.10.3 Financials
      • 20.3.10.4 SWOT Analysis
    • 20.3.11 Johnson & Johnson
      • 20.3.11.1 Company Overview
      • 20.3.11.2 Product Portfolio
      • 20.3.11.3 Financials
      • 20.3.11.4 SWOT Analysis
    • 20.3.12 Merck & Co. Inc.
      • 20.3.12.1 Company Overview
      • 20.3.12.2 Product Portfolio
      • 20.3.12.3 Financials
      • 20.3.12.4 SWOT Analysis
    • 20.3.13 Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
      • 20.3.13.1 Company Overview
      • 20.3.13.2 Product Portfolio
      • 20.3.13.3 Financials
      • 20.3.13.4 SWOT Analysis
    • 20.3.14 Novavax Inc.
      • 20.3.14.1 Company Overview
      • 20.3.14.2 Product Portfolio
      • 20.3.14.3 Financials
      • 20.3.14.4 SWOT Analysis
    • 20.3.15 Panacea Biotec Ltd.
      • 20.3.15.1 Company Overview
      • 20.3.15.2 Product Portfolio
    • 20.3.16 Pfizer Inc.
      • 20.3.16.1 Company Overview
      • 20.3.16.2 Product Portfolio
      • 20.3.16.3 Financials
      • 20.3.16.4 SWOT Analysis
    • 20.3.17 Sanofi Pasteur SA (Sanofi SA)
      • 20.3.17.1 Company Overview
      • 20.3.17.2 Product Portfolio
      • 20.3.17.3 Financials
      • 20.3.17.4 SWOT Analysis
    • 20.3.18 Serum Institute of India Pvt. Ltd.
      • 20.3.18.1 Company Overview
      • 20.3.18.2 Product Portfolio
    • 20.3.19 Takeda Pharmaceutical Company Limited
      • 20.3.19.1 Company Overview
      • 20.3.19.2 Product Portfolio
      • 20.3.19.3 Financials
      • 20.3.19.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Vaccine Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Vaccine Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Vaccine Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Vaccine Market: Breakup by Patient Type (in %), 2024
  • Figure 6: Global: Vaccine Market: Breakup by Indication (in %), 2024
  • Figure 7: Global: Vaccine Market: Breakup by Route of Administration (in %), 2024
  • Figure 8: Global: Vaccine Market: Breakup by Product Type (in %), 2024
  • Figure 9: Global: Vaccine Market: Breakup by Treatment Type (in %), 2024
  • Figure 10: Global: Vaccine Market: Breakup by End User (in %), 2024
  • Figure 11: Global: Vaccine Market: Breakup by Distribution Channel (in %), 2024
  • Figure 12: Global: Vaccine Market: Breakup by Region (in %), 2024
  • Figure 13: Global: Vaccine (Conjugate Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Vaccine (Conjugate Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Vaccine (Inactivated and Subunit Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Vaccine (Inactivated and Subunit Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Vaccine (Live Attenuated Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Vaccine (Live Attenuated Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Vaccine (Recombinant Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Vaccine (Recombinant Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Vaccine (Toxoid Vaccines) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Vaccine (Toxoid Vaccines) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Vaccine (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Vaccine (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Vaccine (Paediatric) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Vaccine (Paediatric) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Vaccine (Adult) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Vaccine (Adult) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Vaccine (Bacterial Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Vaccine (Bacterial Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Vaccine (Meningococcal Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Vaccine (Meningococcal Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Vaccine (Pneumococcal Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Vaccine (Pneumococcal Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Vaccine (Diphtheria/Tetanus/Pertussis-DPT) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Vaccine (Diphtheria/Tetanus/Pertussis-DPT) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Vaccine (Tuberculosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Vaccine (Tuberculosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Vaccine (Haemophilus Influenzae-Hib) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Vaccine (Haemophilus Influenzae-Hib) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Vaccine (Typhoid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Vaccine (Typhoid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Vaccine (Other Bacterial Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Vaccine (Other Bacterial Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Global: Vaccine (Viral Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Global: Vaccine (Viral Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Global: Vaccine (Hepatitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Global: Vaccine (Hepatitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Global: Vaccine (Influenza) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Global: Vaccine (Influenza) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Global: Vaccine (Human Papillomavirus-HPV) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Global: Vaccine (Human Papillomavirus-HPV) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Global: Vaccine (Measles/Mumps/Rubella-MMR) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Global: Vaccine (Measles/Mumps/Rubella-MMR) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Global: Vaccine (Rotavirus) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Global: Vaccine (Rotavirus) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Global: Vaccine (Herpes Zoster) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Global: Vaccine (Herpes Zoster) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Global: Vaccine (Varicella) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Global: Vaccine (Varicella) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Global: Vaccine (Japanese Encephalitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Global: Vaccine (Japanese Encephalitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Global: Vaccine (Rubella) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Global: Vaccine (Rubella) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Global: Vaccine (Polio) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Global: Vaccine (Polio) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Global: Vaccine (Rabies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Global: Vaccine (Rabies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Global: Vaccine (Dengue) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Global: Vaccine (Dengue) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Global: Vaccine (Other Viral Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Global: Vaccine (Other Viral Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Global: Vaccine (Intramuscular and Subcutaneous Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Global: Vaccine (Intramuscular and Subcutaneous Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Global: Vaccine (Oral Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Global: Vaccine (Oral Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Vaccine (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Global: Vaccine (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Vaccine (Multivalent Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Global: Vaccine (Multivalent Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Global: Vaccine (Monovalent Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Global: Vaccine (Monovalent Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Global: Vaccine (Preventive Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Global: Vaccine (Preventive Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Global: Vaccine (Therapeutic Vaccine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Global: Vaccine (Therapeutic Vaccine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Global: Vaccine (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Global: Vaccine (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Global: Vaccine (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Global: Vaccine (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Global: Vaccine (Vaccination Centres) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Global: Vaccine (Vaccination Centres) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Global: Vaccine (Academic and Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 94: Global: Vaccine (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 95: Global: Vaccine (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 96: Global: Vaccine (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 97: Global: Vaccine (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 98: Global: Vaccine (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 99: Global: Vaccine (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 100: Global: Vaccine (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 101: Global: Vaccine (Institutional Sales) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 102: Global: Vaccine (Institutional Sales) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 103: Global: Vaccine (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 104: Global: Vaccine (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 105: North America: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 106: North America: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 107: United States: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 108: United States: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 109: Canada: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 110: Canada: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 111: Asia Pacific: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 112: Asia Pacific: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 113: China: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 114: China: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 115: Japan: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 116: Japan: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 117: India: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 118: India: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 119: South Korea: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 120: South Korea: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 121: Australia: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 122: Australia: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 123: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 124: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 125: Europe: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 126: Europe: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 127: Germany: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 128: Germany: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 129: France: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 130: France: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 131: United Kingdom: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 132: United Kingdom: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 133: Italy: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 134: Italy: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 135: Spain: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 136: Spain: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 137: Russia: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 138: Russia: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 139: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 140: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 141: Latin America: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 142: Latin America: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 143: Brazil: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 144: Brazil: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 145: Mexico: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 146: Mexico: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 147: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 148: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 149: Middle East and Africa: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 150: Middle East and Africa: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 151: Turkey: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 152: Turkey: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 153: GCC Countries: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 154: GCC Countries: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 155: Israel: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 156: Israel: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 157: Others: Vaccine Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 158: Others: Vaccine Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 159: Global: Vaccine Industry: SWOT Analysis
  • Figure 160: Global: Vaccine Industry: Value Chain Analysis
  • Figure 161: Global: Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Vaccine Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Vaccine Market Forecast: Breakup by Patient Type (in Million USD), 2025-2033
  • Table 4: Global: Vaccine Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 5: Global: Vaccine Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: Vaccine Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 7: Global: Vaccine Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 8: Global: Vaccine Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 9: Global: Vaccine Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 10: Global: Vaccine Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 11: Global: Vaccine Market: Competitive Structure
  • Table 12: Global: Vaccine Market: Key Players